Inflation type one error [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2019-11-08 16:21 (1186 d 13:27 ago) – Posting: # 20767
Views: 3,148

Hi PharmCat,

❝ But when CI dynamically changing I think there is no good definition for TIE.


I guess you mean that the acceptance range changes (depending on the \(s_{wR}\)). The CI is not affected.

❝ For fixed CI TIE means that real GMR may be outside permissible range with this chance.


Yep. For fixed limits the TIE is defined based on the Null of bioinquivalence. Directly accessible as the power for GMR exactly at one of the limits.

library(PowerTOST)
CV     <- 0.3
n      <- 34
design <- "2x2x4"
GMR    <- 1.25
# exact
power.TOST(CV = CV, n = n, theta0 = GMR, design = design)
# [1] 0.05
# simulations
power.TOST.sim(CV = CV, n = n, theta0 = GMR, design = design, nsims = 1e6)
# [1] 0.050097


You can plug in any CV, n, design and the TIE will never exceed nominal α.

❝ Very touching assumption to consider that TIE for RSABE is a chance when GMR outside 0.8-1.25 and with this comprehension make CI range wider. Really in this situation TIE not the same as in fixed case.


Here the trouble starts (see what I wrote above). What we are doing here is actually HARKing (Hypothesizing After the Results are Known). Not exactly but we definitely generate the Null from the data. Apart from the TIE-issues every product approved by RSABE/ABEL followed its own rules. From a consumer’s perspective this is not fortunate.

❝ But people want to make ABE for high-variable drug and try to do this :cool: it's like attempt to trick statistics...


Not sure what you mean here. Can you elaborate?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
40 visitors (0 registered, 40 guests [including 19 identified bots]).
Forum time: 05:48 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5